KPIs & Operating Metrics(New)

Balance Sheet

Cash Flow Statement

Acquisitions Amortization of Goodwill Amortization of Goodwill Amortizatization of Intangibles Amortizatization of Intangibles Asset Writedowns and Impairment Asset Writedowns and Impairment Capital Expenditures Capital Expenditures Cash from Financing Activities Cash from Financing Activities Cash from Investing Activities Cash from Investing Activities Cash from Operations Cash from Operations Cash from Restructuring Change in Accured Expenses Change in Accured Expenses Change in Acquisitions & Divestments Change in Acquisitions & Divestments Change in Cash Change in Inventory Change in Inventory Change in Receivables Change in Receivables Change in Taxes Change in Taxes Change in Working Capital Change in Working Capital Deferred Taxes Depreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and Depletion Depreciation and Depletion Divestments Dividends Paid - Common Dividends Paid - Common Exchange Rate Effect Exchange Rate Effect Free Cash Flow Free Cash Flow Gains from Investment Securities Gains from Investment Securities Gains from Sales and Divestitures Gains from Sales and Divestitures Long-Term Debt Issuances Long-Term Debt Repayments Net Cash Flow Net Cash Flow Net Income Non-cash Items Non-cash Items Other Working Capital Changes Other Working Capital Changes Other financing activities Other financing activities Preferred Shares Issued Share-based Compensation Share-based Compensation Shares Issued Shares Repurchased Short-Term Debt issuances Short-Term Debt repayments

Daily Values

Growth Metrics

Teva Pharmaceutical Industries (TEVA) Amortization of Goodwill (2016 - 2024)

Teva Pharmaceutical Industries filings provide 3 years of Amortization of Goodwill readings, the most recent being $280.0 million for Q4 2024.

On a quarterly basis, Amortization of Goodwill changed N/A to $280.0 million in Q4 2024 year-over-year; TTM through Dec 2025 was $280.0 million, a 78.12% decrease, with the full-year FY2024 number at $1.3 billion, up 82.86% from a year prior.
Amortization of Goodwill hit $280.0 million in Q4 2024 for Teva Pharmaceutical Industries, down from $600.0 million in the prior quarter.
In the past five years, Amortization of Goodwill ranged from a high of $600.0 million in Q3 2024 to a low of $280.0 million in Q4 2024.